Genetic Technologies traded at $1.21 this Friday July 1st, increasing $0.05 or 4.31 percent since the previous trading session. Looking back, over the last four weeks, Genetic Technologies gained 2.42 percent. Over the last 12 months, its price fell by 71.05 percent. Looking ahead, we forecast Genetic Technologies to be priced at 1.25 by the end of this quarter and at 1.17 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.21
Daily Change
4.31%
Yearly
-71.05%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acasti Pharma 0.83 -0.03 -3.10% 47.26%
Addus HomeCare 84.62 1.34 1.61% -4.80%
BioScrip 28.53 0.74 2.66% 30.33%
Standard Biotools Inc 1.59 -0.01 -0.63% -72.77%
Genetic Technologies 1.21 0.05 4.31% -71.05%
Laboratory Of America 240.94 6.58 2.81% -13.32%
NanoString Technologies 13.15 0.45 3.54% -79.00%
Pacific Biosciences Of California 4.47 0.05 1.13% -86.65%
Repligen 166.52 4.12 2.54% -17.52%
Bio Techne 353.18 6.54 1.89% -21.44%
Thermo Fisher Scientific 548.27 4.99 0.92% 6.81%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%

Genetic Technologies
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company focuses on the development and commercialization of genetic risk assessment technology for contracting cancer and other chronic diseases. The Company operates through two geographic segments: Australia and United states of America (USA). Australia segment is the home country of the parent entity and the location of the Company's genetic testing and licensing operations. USA segment is the home of Phenogen Sciences Inc. and GeneType Corporation. The Company’s products include GeneType for Breast Cancer is a test that can determine a woman's risk of developing sporadic breast cancer over a period of time; GeneType for Colorectal Cancer is a test that can determine a patient's risk of developing colorectal cancer over a period of time. The Company focuses on development its Germline testing division for hereditary testing.